Bhas Dani

Bhas Dani, MS, Ph.D., joined Soteria in 2021, as SVP, Chief Technical Officer bringing over 20 years of experience in CMC development and manufacturing of biologics and small molecules. Most recently, Dr. Dani led the Biologics Product Development function at AbbVie (Allergan) and was responsible for all aspects of drug product development for their biologics portfolio. Prior to joining AbbVie, Dr. Dani led the Pharmaceutical Development function at Novartis where he was responsible for biologic drug product development from candidate selection through clinical development and product commercialization. Prior to Novartis, Dr. Dani served in positions of increasing responsibility at Nektar Therapeutics and Chiron Corporation. Dr. Dani has led the development of new biologic products through all phases of clinical development and successfully guided them through licensure (BLA and MAA). His experience includes developing a wide range of biologic modalities such as peptides, proteins, monoclonal antibodies, bi-specifics, antibody-drug conjugates, complex toxins, viruses for gene therapy, and bacteria for the microbiome. Dr. Dani has made many original scientific contributions to the fields of pharmaceutical sciences and biotechnology including authoring and reviewing numerous publications in international journals and as an inventor on patent applications. Dr. Dani received his Masters in Pharmaceutical Sciences from Auburn University and his Ph.D. in Pharmaceutical Sciences from the University of Kentucky.